You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Promega would first seek clearance for an assay that detects dMMR in colorectal cancer patients, and could seek a far broader clearance in the long term.
The test, which is currently for research use only, uses fluorescent multiplex PCR to co-amplify seven markers for analysis of the MSI-high phenotype.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
The belief among genomics experts that one day drugs would be given based on genomic abnormalities that cut across tumor types became reality this week.
In a milestone for the cancer community, the agency approved Keytruda for the genomic features of a cancer, not where the tumor occurs in the body.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
Merck will provide OpGen with access to its library of bacterial pathogens in order to support OpGen's development of rapid DNA tests and a pathogens database.
Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
The gene expression assay, which targets 18 markers, is being used by Merck in three new Phase III clinical trials to expand the indication for Keytruda.